Skip to main
SIBN

SI-BONE Inc (SIBN) Stock Forecast & Price Target

SI-BONE Inc (SIBN) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

SI-BONE is a strong investment opportunity due to its record number of active physicians, continued revenue growth, and expanding product portfolio. With a proven track record of delivering above-peer growth, a capital-light business model, and strong gross margins, SI-BONE has a unique position as a leader in the minimally-invasive sacroiliac joint fusion market. While potential risks such as changes in reimbursement coverage and competitive dynamics must be monitored, SI-BONE's partnership with Smith & Nephew and upcoming product launches provide significant growth potential in the near future.

Bears say

SI-BONE is currently experiencing strong revenue growth and a favorable outlook for the future due to potential contributions from partnerships, expansion into new markets, proposed reimbursement changes, and the launch of a new product. However, there is potential for downward pressure on average selling prices and the company's profitability outlook is improving but still has room for growth. Overall, SI-BONE's revenue growth looks sustainable due to multiple products and tailwinds, but the stock may face pressure due to sector-wide multiple compression.

SI-BONE Inc (SIBN) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of SI-BONE Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About SI-BONE Inc (SIBN) Forecast

Analysts have given SI-BONE Inc (SIBN) a Strong Buy based on their latest research and market trends.

According to 6 analysts, SI-BONE Inc (SIBN) has a Strong Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

SI-BONE Inc (SIBN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.